The Company's Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A) has been published on the OTC Markets platform as part of this quarterly disclosure, adhering to the comprehensive reporting standards typical of a reporting issuer, even though the Company is not currently designated as a reporting issuer.
Investors and shareholders can review the detailed operational analysis specifically on pages 18–23 of the filed quarterly report at:
https://www.otcmarkets.com/file/company/financial-report/564647/content
The quarterly filing also outlines a comprehensive operational and balance sheet cleanup of legacy shell obligations, establishing a streamlined financial foundation to advance its proprietary neurological drug pipeline and advanced diagnostic applications.
PCAOB Audit Progress & Strategic Up-listing Mandate
To further its commitment to institutional-grade transparency and to accelerate its capital markets strategy, the Company is currently in the process of executing its PCAOB audit under the leadership of its recently appointed CFO and COO, Angelo Pizzuto. Achieving a finalized PCAOB audit is a strict regulatory requirement that supports the Company's planned uplisting application to the OTCQB or OTCQX market tiers.
The PCAOB audit pre-work formally commenced on May 6, 2026, with the hiring of an independent, third-party pre-audit accounting preparation firm. This firm has been actively optimizing the Company's financial records and preparing technical accounting memos to ensure total audit readiness. Because this third-party ...
